Susquehanna International Group, LLP Immunovant, Inc. Put Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$27.51 - $27.51 $1.46 Million - $1.46 Million	53,100 Added 49.17%	161,100 $4.43 Million
Q2 2024 Aug 15, 2024	SELL	$25.1 - $31.61 $3.64 Million - $4.58 Million	-145,000 Reduced 57.31%	108,000 $2.85 Million
Q1 2024 May 07, 2024	SELL	$30.27 - $43.79 $5.74 Million - $8.3 Million	-189,600 Reduced 42.84%	253,000 $8.17 Million
Q4 2023 Feb 14, 2024	BUY	$31.31 - $44.19 $1.46 Million - $2.05 Million	46,500 Added 11.74%	442,600 $18.6 Million
Q3 2023 Nov 14, 2023	BUY	$18.55 - $39.96 $5.84 Million - $12.6 Million	314,800 Added 387.21%	396,100 $15.2 Million
Q2 2023 Aug 11, 2023	BUY	$14.2 - $23.75 $629,060 - $1.05 Million	44,300 Added 119.73%	81,300 $1.54 Million
Q1 2023 May 16, 2023	BUY	$15.27 - $19.72 $564,990 - $729,640	37,000 New	37,000 $573,000

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.